By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and reduced the risk of disease progression or death,

Research from investigators at Rutgers Cancer Institute of New Jersey and the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, shows the intracellular process of autophagy plays a role in the development of prostate cancer.

A proof-of-concept study has created a blueprint for producing prostate cancer treatment more efficiently. Researchers at the University of Missouri, Cancer Targeted Technology (CTT) and Isotherapeutics Group (ITG) discovered an innovative method to speed production of a cancer-fighting drug candidate.

A UCLA neurobiology professor and prostate cancer survivor discuss using artificial intelligence to map his disease and inform treatment decisions. Artificial intelligence (AI) has the potential to “level the playing field” for patients with cancer ...

The breakthrough at Columbia University lays the groundwork for future clinical studies aimed at developing new treatments.

Researchers at Columbia University Irving Medical Center have identified a gene that drives the development of neuroendocrine prostate cancer (NEPC), an aggressive form of the disease. The study published in the Journal of Experimental Medicine (JEM),

Reginald Tucker-Seeley, MA, ScM, ScD, concludes the program with advice for caregivers and patients with prostate cancer to maximize the benefit of treatment. This is a synopsis of an Educated Patient Sound Bites series featuring Alicia Morgans, MD, MPH ...

The UK National Screening Committee has decided against vouching for population-wide testing, so who will get access and who will miss out?

A breakthrough in treating an aggressive form of prostate cancer could boost survival rates, according to new research. American scientists have identified a gene that drives the development of neuroendocrine prostate cancer (NEPC).

If the results find a more reliable way of detecting tumours that require treatment then advisors could recommend expanding eligibility for screening to a wider group of men.